Baxter International is a healthcare company that focuses on developing and providing a wide range of medical products and services to enhance patient care
The company specializes in creating innovative therapies and solutions for various health conditions, including renal and hospital care. With a strong emphasis on sustainability and improving patient outcomes, Baxter manufactures essential medical devices, pharmaceuticals, and biotechnology products that support the treatment of chronic diseases and acute medical conditions. Their commitment to research and development drives advancements in healthcare technology, helping to meet the needs of healthcare professionals and patients worldwide.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified stocks, starting with Stryker (NYSESYK).
Healthcare is the top-performing sector in the market, up 7.31% and outperforming the S&P 500 by 4.2x. Looks like the rumors of its death were indeed GREATLY EXAGGERATED.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4, starting with Baxter (NYSEBAX).
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQNEOG) and its peers.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Healthcare company Baxter International (NYSEBAX) beat Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $2.75 billion. On the other hand, next quarter’s revenue guidance of $2.58 billion was less impressive, coming in 1.4% below analysts’ estimates. Its non-GAAP profit of $1.89 per share was significantly above analysts’ consensus estimates.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Baxter International exceeded Q4 earnings and revenue estimates, with strong pharmaceutical sales. The company issued a mixed 2025 outlook amid cost pressures.
This afternoon felt like either a fund blew up or the margin clerks were taking a bunch of dumb over-leveraged money out to the woodshed to put them out of their misery.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Baxter International (BAX) cut its dividend because of the upcoming sale of the Kidney Care business, high debt and leverage, lower earnings per share, and free cash flow.
